The content on this site is intended for healthcare professionals only
Dr George Follows (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) talks with Dr Andrew Zelenetz (Memorial Sloan Kettering Cancer Centre, New York, USA) at the BSH 2016 conference in Glasgow.
Dr Zelenetz was presenting in Glasgow with a late breaking poster detailing the outcomes of a trial to treat relapsed chronic lymphocytic leukaemia with a combination of idelalisib, bendamustine and rituximab
The results of the trial report overwhelming efficacy of the combination compared to placebo or bendamustine with rituximab.
Dr Follows and Dr Zelenetz discuss the impact of these results, considering risks such as infection, and the value of the combined IBR arm of the trial against BR alone, or the as-yet-unreported IR arm.
Study details can be found here.
This video is supported by an educational grant from Gilead.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Relapsed refractory multiple myeloma
Neo-adjuvant therapy for different cancers in the Philippines
